Summary
Latest filing:
Salvia Investment GmbH is 10% Owner of Bambusa Therapeutics, Inc. (BBTX). 1 SEC Form 4 filing on record, dated 2 November 2026. Most recent open-market trade: bought $6.00M of BBTX on 2 November 2026. Lifetime open-market purchases: $6.00M.
Recent transactions
2The latest 2 SEC Form 4 transactions reported by Salvia Investment GmbH.
Trading pattern
InsiderAlpha's records for Salvia Investment GmbH go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. The typical open-market purchase is $6.00M (1 buy totaling $6.00M). The largest single buy on record is $6.00M of BBTX in 2026. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Salvia Investment GmbH files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Helmut Wolfgang Jeggle - $6.00M in BBTX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is Salvia Investment GmbH?
Salvia Investment GmbH is an investment firm, tracked as 10% Owner of Bambusa Therapeutics, Inc. (BBTX). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Salvia Investment GmbH submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Salvia Investment GmbH been buying or selling stock?
Recorded transactions: 1 open-market purchase ($6.00M) and 0 open-market sales across all tracked filings.